Sonoma Pharmaceuticals (SNOA) Equity Average (2011 - 2025)

Sonoma Pharmaceuticals' Equity Average history runs 15 years deep, the most recent figure standing at $3.6 million for Q4 2025.

• In Q4 2025, Equity Average fell 29.38% year-over-year to $3.6 million; the TTM figure through Dec 2025 stood at $3.6 million (down 29.38% YoY), while the FY2025 annual figure was $5.3 million, down 25.27% from the prior year.
• Equity Average was $3.6 million for Q4 2025 at Sonoma Pharmaceuticals, down from $3.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $11.3 million in Q4 2021 to a low of $3.6 million in Q4 2025.
• Historically, Equity Average has averaged $6.5 million across 5 years, with a median of $6.4 million in 2022.
• Biggest YoY gain for Equity Average was 66.83% in 2022; the steepest drop was 44.41% in 2022.
• A 5-year view of Equity Average shows it stood at $11.3 million in 2021, then slumped by 44.41% to $6.3 million in 2022, then dropped by 1.69% to $6.2 million in 2023, then declined by 17.34% to $5.1 million in 2024, then fell by 29.38% to $3.6 million in 2025.
• The last three Equity Average figures came in at $3.6 million (Q4 2025), $3.9 million (Q3 2025), and $4.2 million (Q2 2025), per Business Quant data.